Journal of Pain Management and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Pain Management and Therapy (2023) Volume 7, Issue 3

Epidemiology of Kaposi Sarcoma: Prevalence, risk factors, and geographical distribution

 

Ethel Ronald*

Department of Paediatrics, University of Oxford, Oxford, UK

*Corresponding Author:

Ethel Ronald
Department of Paediatrics
University of Oxford
Oxford, UK
E-mail:e.ronal85@med.edu.org

Received:12-Apr-2023,Manuscript No. AAPMT-23-98559; Editor assigned: 15-Apr-2023, PreQC No. AAPMT-23-98559(PQ); Reviewed:29-Apr-2023, QC No. AAPMT-23-98559; Revised:03-May-2023, Manuscript No. AAPMT-23-98559(R); Published:10-May-2023, DOI: 10.35841/aapmt- 7.3.143

Citation: Ronald E. Epidemiology of Kaposi Sarcoma: Prevalence, risk factors, and geographical distribution. J Pain Manage Ther. 2023;7(3):143

Visit for more related articles at Journal of Pain Management and Therapy

Introduction

Kaposi Sarcoma (KS) is a rare form of cancer that primarily affects the skin, but can also involve other organs such as the lungs, gastrointestinal tract, and lymph nodes. It is characterized by the abnormal growth of blood vessels and the presence of spindle-shaped cells. The epidemiology of KS provides valuable insights into its prevalence, risk factors, and geographical distribution, helping researchers and healthcare professionals understand the patterns and determinants of this disease. This article aims to provide a comprehensive overview of the epidemiology of Kaposi sarcoma, highlighting its global burden and associated risk factors.

 

Prevalence of kaposi sarcoma

HI associated kaposi sarcoma: The advent of the HIV/AIDS epidemic in the 1980s led to a dramatic increase in the incidence of KS, particularly among individuals with advanced HIV infection. HIV-associated KS is the most common form of the disease globally and accounts for the majority of cases in resource-limited settings, where HIV prevalence is high[1].

Endemic kaposi sarcoma: Endemic KS occurs primarily in sub-Saharan Africa, particularly in equatorial regions. It affects predominantly children and young adults and is associated with a distinct human herpesvirus-8 (HHV-8) transmission pattern. Endemic KS has been prevalent in certain geographic areas for centuries.

Classic kaposi sarcoma: Classic KS mainly affects elderly individuals of Mediterranean, Eastern European, or Middle Eastern descent. It has a relatively low incidence compared to HIV-associated KS and is more prevalent in specific ethnic groups[2].

Iatrogenic kaposi sarcoma: Iatrogenic KS occurs as a result of immunosuppressive therapy following organ transplantation. The prevalence of iatrogenic KS has decreased with improvements in transplantation techniques and immunosuppressive regimens.

 

Risk factors for kaposi sarcoma

Human Herpesvirus-8 (HHV-8) infection: HHV-8, also known as Kaposi sarcoma-associated herpesvirus (KSHV), is a necessary but not sufficient cause of KS. It is primarily transmitted through sexual contact, but non-sexual routes such as saliva and blood transfusion can also contribute to its spread.

Immunosuppression: Individuals with compromised immune systems, such as those living with HIV/AIDS, are at an increased risk of developing KS. The severity of immunosuppression, measured by CD4 cell count in HIV-infected individuals, correlates with the risk of KS development[3].

Genetic factors: Classic KS has been associated with specific genetic factors, including polymorphisms in genes involved in immune function and inflammation. These genetic factors may contribute to an individual's susceptibility to developing the disease.

Geographic factors: The geographical distribution of KS is closely linked to the prevalence of HHV-8 infection. Areas with a high prevalence of HHV-8, such as sub-Saharan Africa, show a higher incidence of KS. Additionally, regions with a high prevalence of HIV/AIDS have seen an increased burden of HIV-associated KS[4].

 

Emerging trends and future considerations

Antiretroviral therapy: The widespread availability of antiretroviral therapy has significantly improved the prognosis and reduced the incidence of HIV-associated KS in many parts of the world. Efforts to improve access to antiretroviral therapy in resource-limited settings can contribute to further reductions in the burden of HIV-associated KS.

HHV-8 vaccines: The development of vaccines against HHV-8 is an active area of research. A successful vaccine could potentially prevent HHV-8 infection and subsequently reduce the incidence of KS, particularly in high-risk populations

Early detection and screening: Early detection and screening programs can help identify individuals at risk of developing KS, enabling timely intervention and treatment. These programs may be particularly beneficial in regions with a high burden of HIV/AIDS and endemic KS.

Global collaboration: Given the complex interplay between HHV-8, HIV/AIDS, and other risk factors, global collaboration is crucial in understanding the epidemiology of KS. Collaborative efforts can facilitate the sharing of knowledge, resources, and best practices to improve prevention, diagnosis, and treatment strategies worldwide[5].

Conclusion

The epidemiology of Kaposi sarcoma is influenced by various factors, including the prevalence of HHV-8 infection, the immune status of the affected population, and geographic distribution. HIV-associated KS remains a significant concern, particularly in regions with a high prevalence of HIV/AIDS. Endemic KS is predominantly observed in sub-Saharan Africa, while classic KS is more common in specific ethnic groups in North America, Europe, and certain parts of Asia. Understanding the epidemiology of KS is crucial for implementing effective prevention and control measures, improving access to treatment, and reducing the global burden of this rare cancer. Continued research, collaboration, and targeted interventions are needed to address the challenges associated with Kaposi sarcoma and improve the outcomes for affected individuals worldwide.

References

  1. Gao SJ, Kingsley L, Hoover DR, et al.Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus–related latent nuclear antigens before the development of Kaposi's sarcoma.Engl J Med. 1996;335(4):233-41.

    2. Indexed at, Google Scholar, Cross Ref

  2. Beral V.Epidemiology of Kaposi's sarcoma.Cancer Surv. 1991;10:5-22.

    3. Indexed at, Google Scholar,

  3. Laor Y, Schwartz RA.Epidemiologic aspects of American Kaposi's sarcoma.J Surg Oncol. 1979;12(4):299-303.

    4. Indexed at, Google Scholar, Cross Ref

  4. Ross RK, Casagrande JT, Dworsky RL, et al.Kaposi's sarcoma in Los Angeles, California.J Natl Cancer Inst. 1985;75(6):1011-5.

    5. Indexed at, Google Scholar

  5. Slavin G, Cameron HM, Singh H.Kaposi's sarcoma in mainland Tanzania: A report of 117 cases.Br J Cancer. 1969;23(2):349.

    6. Indexed at, Google Scholar, Cross Ref

Get the App